On April 16, 2026, Vir Biotechnology, Inc. announced the closing of its global collaboration and licensing agreement with Astellas for VIR-5500 in metastatic prostate cancer, securing a US$240,000,000 ...
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...
Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of ...
9d
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the must-buy small cap stocks to buy. On April 13, Vir Biotechnology, Inc.
Despite interest from GSK and high hopes of leading the next generation of influenza A prophylaxis, Vir Biotechnology’s monoclonal antibody has failed its first phase 2 challenge. The PENINSULA study ...
UKRAINE - 2022/01/23: In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) ...
Vir Biotechnology is narrowing its focus. Sitting on $1.9 billion, the infectious disease specialist has decided to stop work on its innate immunity small-molecule platform as part of its efforts to ...
Vir Biotechnology's coronavirus treatment is losing steam. The company's pipeline looks somewhat promising on first glance. But the biotech's most recent data readout was not encouraging. This could ...
On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results